A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma
18 Years
70 Years
Both
Multiple Myeloma and Plasma Cell Neoplasm
Trial Information
A Multicenter Dosimetry Trial to Evaluate Radiation Absorbed Dose From Holmium-166-DOTMP in Patients With Multiple Myeloma
OBJECTIVES:
- Determine the radiation absorbed dose of holmium Ho 166 DOTMP to the kidney in patients
with multiple myeloma, based on whole body gamma camera image data for comparison with
that obtained using an ICRP mathematical model.
- Determine the average marrow dose of this drug in these patients using gamma camera
whole body counts in patients receiving this drug.
- Determine the pharmacokinetics of this drug in these patients.
- Compare marrow dose estimates determined from gamma camera whole-body counts and
thyroid uptake probe counts in patients receiving this drug.
- Evaluate intra-patient variability of the uptake of this drug in the bone with repeat
tests.
- Determine whether the biodistribution and dosimetry is influenced by administering this
drug as a bolus compared to a 15-minute infusion in these patients.
- Compare the reduction in dose rate from the 15-minute infusion vs the bolus injection
of this drug to estimate the effect on kidney exposure in these patients.
- Determine the renal transit time for each patient after bolus injection of this drug
and assess whether this information improves the dose estimate to kidney with the
mathematical model.
- Determine whether there is correlation of renal transit time from technetium Tc
99m-diethylenetriaminepentaacetic acid (DTPA) with holmium Ho 166 DOTMP.
- Determine the adverse events in patients receiving this drug.
- Determine the efficacy of a targeted therapy dose of holmium Ho 166 DOTMP with
melphalan followed by autologous peripheral blood stem cell transplantation in these
patients.
OUTLINE: This is a multicenter study. Patients are entered into one of two cohorts.
- Cohort A: Patients receive a diagnostic dose of holmium Ho 166 DOTMP IV over 15 minutes
on day 1 and then IV bolus on day 8.
- Cohort B: Patients receive a diagnostic dose of holmium Ho 166 DOTMP IV over 15 minutes
on days 1 and 8.
After each diagnostic dose, patients in both cohorts also undergo gamma camera imaging of
the whole body on days 1 and 8.
Approximately 1-3 weeks later, patients in both cohorts who demonstrate adequate uptake of
the first diagnostic dose of holmium Ho 166 DOTMP into the bone marrow then receive
therapeutic holmium Ho 166 DOTMP IV over 15 minutes once between days -13 to -10 followed by
melphalan IV over 20-30 minutes once between days -10 to -1. Patients undergo autologous
peripheral blood stem cell transplantation on day 0.
Patients are followed monthly for 1 year and then every 3 months for 1 year.
PROJECTED ACCRUAL: A minimum of 12 patients (6 per cohort) will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of multiple myeloma (MM)
- Patients with a prior diagnosis of monoclonal gammopathy of undetermined
significance (MGUS) or smoldering myeloma are eligible if they progressed and
met the criteria for diagnosis of MM
- No non-secretory MM
- No symptomatic MGUS, smoldering MM, or indolent MM
- No solitary bone or extramedullary plasmacytoma
- No immunoglobulin M myeloma
- Prior induction therapy for myeloma required
- Responding, stable, or progressive disease after induction therapy, or relapsed
disease
- Candidate for autologous hematopoietic stem cell transplantation
- Prior stem cell mobilization with chemotherapy and growth factors according to
institutional procedures
- Availability of at least 2,000,000 CD34+ cells/kg
PATIENT CHARACTERISTICS:
Age
- 18 to 70
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Bilirubin no greater than 2 mg/dL
- SGPT no greater than 2 times upper limit of normal
- No clinical evidence of amyloidosis of the liver
Renal
- Creatinine no greater than 2.0 mg/dL
- Creatinine clearance at least 45 mL/min
- Renal ultrasound normal
- No clinical evidence of amyloidosis of the kidney
- No urinary obstruction in the renal pelvis, ureter, or bladder outlet by ultrasound
Cardiovascular
- Ejection fraction at least 50% with no evidence of amyloidosis by echocardiogram
- No clinical evidence of amyloidosis of the heart
- No uncontrolled arrhythmia
- No symptomatic cardiac disease
Pulmonary
- FEV1, FVC, and DLCO at least 60%
- No symptomatic pulmonary disease
- No clinical evidence of amyloidosis of the lungs
Other
- No known allergy to vitamin C or bisphosphonates
- No known hypersensitivity to technetium Tc 99m phosphorus radiopharmaceuticals (e.g.,
technetium Tc 99m-methylene diphosphonate)
- No concurrent illness that would severely limit life expectancy
- No symptoms, physical findings, or radiographic evidence of cord compression
- No clinical evidence of amyloidosis of the autonomic nervous system or
gastrointestinal tract
- No prior noncompliance in other studies
- No other malignancy within the past 5 years except treated indolent skin cancers or
carcinoma in situ of the cervix
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- No prior stem cell or bone marrow transplantation
- No concurrent maintenance therapy comprising interferon or thalidomide
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- See Disease Characteristics
- No concurrent maintenance therapy comprising dexamethasone
Radiotherapy
- No prior cumulative external-beam radiotherapy (EBRT) to more than 20% of bone marrow
- No prior cumulative EBRT dose of 30 Gy or more to the spinal cord
- No prior radiotherapy to the bladder
Surgery
- See Disease Characteristics
Other
- At least 4 weeks since prior investigational agents for MM
- At least 4 weeks since other prior experimental therapies for any other condition
- No bisphosphonates for at least 4 weeks before study, during study, and for at least
30 days posttransplantation
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Principal Investigator
Wendy Jenkins
Investigator Role:
Principal Investigator
Investigator Affiliation:
Poniard Pharmaceuticals
Authority:
United States: Federal Government
Study ID:
CDR0000256377
NCT ID:
NCT00045136
Start Date:
January 2002
Completion Date:
Related Keywords:
- Multiple Myeloma and Plasma Cell Neoplasm
- refractory multiple myeloma
- stage I multiple myeloma
- stage II multiple myeloma
- stage III multiple myeloma
- Neoplasms
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Plasmacytoma
Name | Location |
|---|---|
| Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
| University of Texas - MD Anderson Cancer Center | Houston, Texas 77030-4009 |
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham, Alabama 35294-3300 |
| University of California Davis Cancer Center | Sacramento, California 95817 |
| Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus | Nashville, Tennessee 37212 |
